Application of glycyrrhetinic acid and glycyrrhizic acid in preparation of medicines for preventing or treating radioactive soft tissue injury

A technology for soft tissue damage and glycyrrhetinic acid, applied in the fields of food or food additives, health products, and medicines, can solve the problems of human poisoning

Inactive Publication Date: 2014-07-09
XIAMEN LUJIA BIOTECH
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most of these compounds are t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of glycyrrhetinic acid and glycyrrhizic acid in preparation of medicines for preventing or treating radioactive soft tissue injury
  • Application of glycyrrhetinic acid and glycyrrhizic acid in preparation of medicines for preventing or treating radioactive soft tissue injury
  • Application of glycyrrhetinic acid and glycyrrhizic acid in preparation of medicines for preventing or treating radioactive soft tissue injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Experimental animals: 8-week-old C57BL / 6 male mice (purchased from the Experimental Animal Center of Shanghai Academy of Biological Sciences). Observed in the breeding observation room for 3 days before administration, the animals were randomly divided into groups, with an average of 4 groups per cage, the room temperature was 25 degrees, the relative humidity was 50-70%, and the light-dark cycle was 12 hours.

[0051] Irradiation equipment: Electron linear accelerator (Germany SIMENS, PRIMUS600 type), the X-ray dose rate produced is 2Gy / min.

[0052] Animal modeling and drug intervention: Experimental animals were randomly divided into 4 groups: normal control group, model solvent group, glycyrrhetinic acid treatment group and positive drug Celebrex treatment group, each with 8 animals. The model solvent group, the glycyrrhetinic acid treatment group and the Celebrex treatment group received a single irradiation of 30Gy on the right hind limb. During the irradiation, t...

Embodiment 2

[0057] Experimental animals: the same as in Example 1.

[0058] Irradiation apparatus: with embodiment 1.

[0059] Animal modeling and drug intervention: Experimental animals were randomly divided into 4 groups: normal control group, model solvent group, glycyrrhetinic acid treatment group and positive drug Celebrex treatment group, 10 each. The model solvent group, the glycyrrhetinic acid treatment group and the positive drug Celebrex treatment group received a single irradiation of 30Gy on the right hind limb. During the irradiation, the mice were fixed in a specially designed fixture. kg (PBS buffer solution), the Celebrex treatment group was given Celebrex 30mg / kg on the same day, the normal control group and the model solvent group were given the same volume of PBS buffer solution, three times a week, and the administration time was 28 days in total.

[0060] After 3 months of irradiation, observe the fibrosis of the right hindlimb (degree of contracture of the right hin...

Embodiment 3

[0063] Experimental animals: the same as in Example 1.

[0064] Irradiation apparatus: with embodiment 1.

[0065] Animal modeling and drug intervention: Experimental animals were randomly divided into 4 groups: normal control group, model solvent group, glycyrrhetinic acid treatment group and positive drug Celebrex treatment group with 4 animals each. The model solvent group, the glycyrrhetinic acid treatment group and the positive drug Celebrex treatment group received a single irradiation of 50Gy on the right hind limb. During the irradiation, the mice were fixed in a specially designed fixture. kg (PBS buffer solution), the Celebrex treatment group was given Celebrex 50mg / kg on the same day, the normal control group and the model solvent group were given the same volume of PBS buffer solution, three times a week, and the administration time was 28 days in total.

[0066] After 7 months of irradiation, observe the fibrosis of the right hind limb (degree of contracture of t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed is use of glycyrrhetinic acid or glycyrrhizic acid in preventing or treating radiation injury of soft tissue. Therefore, glycyrrhetinic acid or glycyrrhizic acid can be used for preparing medicaments for preventing or treating radiation injury of soft tissue. The medicament prepared from glycyrrhetinic acid or glycyrrhizic acid has advantages of low cost, good curative effect, low toxicity and side effect during administration in long term and so on. Glycyrrhetinic acid or glycyrrhizic acid can also be used for preparing health care products, foods or food additives for preventing or treating radiation injury of soft tissue.

Description

technical field [0001] The invention relates to the fields of medicine, health products, food or food additives. Specifically, the present invention relates to glycyrrhetinic acid and the application of glycyrrhizic acid in the preparation of medicines, health care products, food or food additives for preventing or treating radiation soft tissue damage. Background technique [0002] Clinically, radiotherapy has been one of the main means of tumor treatment. However, almost none of the patients who receive radiation are spared radiation damage, including soft tissue damage. Radiation can cause a series of acute and chronic permanent soft tissue reactions and damage, manifested as reversible acute hair loss, ulcers, dermatitis, pigmentation and irreversible skin atrophy, destruction of sebaceous glands and sweat glands, hair loss over time, skin, subcutaneous Soft tissue fibrosis of tissue or muscle, or even radiation necrosis. Seriously affect the quality of life of patien...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704A61K31/56A61P39/00A61P17/16A61P21/00A61P19/08A61P29/00A23L1/30
CPCA61K31/192A23V2002/00A61K31/704A23L1/30A23L1/3002A61K31/56A23L33/105A61P17/16A61P19/08A61P21/00A61P29/00A61P39/00A23V2200/30A23V2200/316A23V2200/318A23V2250/21A23V2250/252
Inventor 张纬建洪金省张亨山韩德平吕文龙
Owner XIAMEN LUJIA BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap